Avenue Therapeutics Inc (ATXI) - News Archive

In the world of biotech investments, dynamic share performance can often reflect not just the inherent qualities of the companies involved but also the broader market sentiments and strategic decisions that shape invest...

In recent days, several significant events have unfolded in the pharmaceutical industry, particularly surrounding Avenue Therapeutics Inc. This article aims to analyze and discuss these events in order to shed light on...

Avenue Therapeutics, a pioneering biopharmaceutical company, has announced an exciting update in the development of a groundbreaking treatment for Spinal and Bulbar Muscular Atrophy (SBMA), commonly known as Kennedy s D...

Avenue Therapeutics Announces Reverse Stock Split: What It Means for InvestorsIn a recent press release, Avenue Therapeutics Inc (Nasdaq: ATXI) announced a 1-for-75 reverse stock split of its common stock. This move, wh...

Avenue Therapeutics Inc., a leading pharmaceutical company, recently presented its groundbreaking preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting. The...

In an exciting development for the healthcare industry, Avenue Therapeutics has recently published a groundbreaking study showcasing the preclinical data of their first-in-class drug, BAER-101, in the treatment of absen...

Avenue Therapeutics Raises $5 Million in Proceeds through Warrant Exercise TransactionsMiami, January 5, 2024 - Avenue Therapeutics, a specialty pharmaceutical company specializing in the development and commercializati...

Avenue Therapeutics Landmark Agreement with FDA for Phase 3 Safety Protocol on IV TramadolAvenue Therapeutics, Inc. (Nasdaq: ATXI), a niche pharmaceutical firm specializing in the development and commercialization of tr...

Avenue Therapeutics Reaches Milestone in Clinical Trial for Treating Spinal and Bulbar Muscular AtrophyAvenue Therapeutics Inc, a leading biopharmaceutical company, recently announced the completion of patient enrollmen...

Avenue Therapeutics Announces Successful Pricing of $5.0 Million Public Offering for Neurologic Disease TherapiesMiami, October 31, 2023 - Avenue Therapeutics, Inc. (Nasdaq: ATXI), a leading specialty pharmaceutical com...